Premium
Role of granulocyte/neutrophil transfusions for haematology/oncology patients in the modern era
Author(s) -
Strauss Ronald G.
Publication year - 2012
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2012.09190.x
Subject(s) - medicine , granulocyte , hematology , granulocyte colony stimulating factor , haematopoiesis , neutropenia , absolute neutrophil count , progenitor cell , hematologic neoplasms , randomized controlled trial , immunology , oncology , intensive care medicine , stem cell , chemotherapy , transplantation , biology , genetics
Summary Infections continue to be a serious problem for severely neutropenic oncology and haematopoietic progenitor cell ( HPC ) transplant patients. Although it is now possible to collect much larger numbers of neutrophils ( PMN s) from donors stimulated with granulocyte colony‐stimulating factor + corticosteroids, the efficacy of these ‘modern’ granulocyte/ PMN transfusions, with higher doses of PMN s, has not been established by convincing randomized control trials. Accordingly, they cannot be recommended for standard therapy at this time.